Press Releases

R&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution YAVNE, Israel, Sept. 26, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,

Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns YAVNE, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated

YAVNE, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its successful participation at the recently concluded 20 th European

YAVNE, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming H.C. Wainwright 25 th Annual Global Investment

EscharEx ® Phase III study protocol : FDA/EM A-aligned ; p atient enrollment commencing early 2024 ; two key research collaborations with wound industry leaders NexoBrid ® U.S. commercial launch timing not anticipated to impact revenue s in 2023-2024 Cash of $ 51.3 million; operating cash runway

MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic

MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics

Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time YAVNE, Israel, Aug. 07, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its

Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement YAVNE, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today

MW005 shown to be safe and well-tolerated Data provide clinical efficacy proof-of-concept based on clearance of target lesions YAVNE, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic